The presence of adverse molecular features most closely correlated with genomic classifier scores, even within low grade ...

The investigators hypothesized that the use of proton therapy for extended lymph node irradiation of the pelvic and ...

Dr. Sutera opened his talk by outlining that he would divide his presentation into three parts: first, defining MMAI; second, discussing its application in oligometastatic prostate cancer; and third, ...

The study aims to accrue up to 41 patients at MD Anderson Cancer Center and partner sites. The study started enrolling in October 2024, and enrollment is ongoing with a primary completion estimate of ...

The 2025 ASTRO annual meeting featured a metastatic prostate cancer session and a discussant presentation by Dr. Comron ...

The 67 th American Society for Radiation Oncology (ASTRO) annual meeting held in San Francisco between September 28 and September 30 was host to the Session16 - GU 4: Quality of Life Outcomes after ...

The co-primary endpoints were safety and efficacy: efficacy defined as ≥25% reduction in rectal rV70 in >75% of balloon patients, and safety defined as non-inferiority in rectal and procedure-related ...

(UroToday.com The 2025 ASTRO annual meeting featured a prostate cancer session and a presentation by Dr. Beth Neilsen ...

This was a single-center, retrospective analysis of 42 patients with MIBC who underwent TMT at the Moffitt Cancer Center ...

Artera Unveils Four Presentations at ASTRO 2025 Illustrating its Multimodal Artificial Intelligence (MMAI) Platform’s Scalability, Speed, and Potential to Personalize Treatment Decisions for Multiple ...

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

AUA 2025: Which Are the Prognostic Implications of a Negative PSMA-PET at the Time of Biochemical Recurrence in Prostate Cancer Patients Treated With Radical Prostatectomy? Selection of Salvage ...